Atlas Trials

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Clinical trial NCT00555724 · COMPLETED

Trial details

NCT number
NCT00555724
Sponsor
Biogen
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors
Start date
2008-01-01
Primary completion
2010-04-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.